Shares of Johnson & Johnson dropped after the announcement of selling its stake in Kenvue.
Stock AI’s forecasts:
🔴 -6.4% short-term ⬇️
🟢 +1.0% long-term ⬆️
Stock AI’s (JNJ) Forecast get (+10.1% Profit)
StockAI’s analysis delivers real-world results. On 06 March 2024, $JNJ ($160.7), StockAI predicted a long-term 🔴 sell signal. It was accurate: 1 month later price dropped to $144.4 (🔴-10.1%). Selling JNJ on this signal yielded a +10.1% profit 💰💰.
JNJ-Johnson & Johnson News
🔴 Johnson & Johnson to sell remaining stake in Kenvue, impacting investor confidence.
🟢 JNJ acquires Proteologix for $850 million, expanding its portfolio for immune-mediated diseases.
🔴 Lawsuit filed against JNJ by cancer victims, raising concerns over legal issues.
🟢 Phase 3 trial results for seltorexant show promise, boosting future prospects.
🔴 Jury rules JNJ must pay $260 million in talc powder lawsuit, leading to financial strain.
🟢 Johnson & Johnson’s experimental drug shows positive results in late-stage trial for depression.
Johnson & Johnson’s stock has been impacted by a series of recent events, with both positive and negative news affecting investor sentiment. The announcement of selling its stake in Kenvue and the lawsuit filed against the company have raised concerns among investors, leading to a decrease in stock price. However, the acquisition of Proteologix and positive trial results for seltorexant have sparked optimism, potentially driving the stock price higher in the long term. The jury ruling in the talc powder lawsuit has added further financial strain on the company, contributing to the negative sentiment. Overall, the stock’s future performance will likely be influenced by the resolution of legal issues, success in drug trials, and overall market conditions. Investors should closely monitor these developments to make informed decisions regarding their investments in Johnson & Johnson.
JNJ-Johnson & Johnson Analyst Ratings
📈 Royal Bank of Canada reiterated their outperform rating on Johnson & Johnson (NYSE:JNJ) stock with a price target of $175.00.
📉 Goldman Sachs initiated coverage on Johnson & Johnson (NYSE:JNJ) with a neutral rating and a price target of $160.00.
📉 Wells Fargo reiterated an Equal Weight rating on Johnson & Johnson (NYSE:JNJ) stock post KVUE shares divestiture.
Sources:
1. Forbes
2. Benzinga
3. Yahoo Finance
4. Investors.com
5. ETF Daily News
Disclaimer
Investors may consider the AI predictions and news summaries as one factor in their investment decisions alongside their own research and risk tolerance.
Ready to analyze your own portfolio?
Get the same AI-powered insights for any stock you choose. It's easy!
